JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205

Volume 15 Issue 06, June 2025

Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

ADVANCES IN ONCOLOGY: THE ROLE OF IMMUNOTHERAPY IN TREATING SOLID TUMORS

5th- year students, Faculty of Pediatrics Samarkand State Medical University

Haydarov Og'abek Ulug'bek ugli

Anvarov Navro'z Anvarovich

Mamatqulov Ismoil G'aybulla ugli

Hayitov Safarali Maxammadi ugli

4th-year student, Faculty of General Medicine Samarkand State Medical University

Adxamov Asror Adxam ugli

Abstract: In the past decade, immunotherapy has revolutionized the field of oncology, offering new hope in the battle against solid tumors. Unlike conventional chemotherapy or radiotherapy, immunotherapy utilizes the patient's immune system to identify and destroy malignant cells. It represents a paradigm shift in cancer treatment, particularly in cases where traditional therapies have failed or proven insufficient. This article provides an in-depth overview of the development, mechanisms, and current applications of immunotherapy in the treatment of solid tumors, including statistical evaluations of efficacy in various cancer types. The article also explores challenges, limitations, and the future direction of immunotherapy in the global fight against cancer.

Keywords: Cancer immunotherapy, immune checkpoint inhibitors, solid tumors, PD-1/PD-L1, CAR-T cells, tumor microenvironment, precision oncology, cancer vaccine, biomarkers, clinical outcomes

Introduction: Cancer remains a leading cause of death worldwide, responsible for approximately 10 million deaths in 2022 alone, with solid tumors accounting for over 85% of all cancer cases. Lung, breast, colorectal, prostate, and stomach cancers are among the most commonly diagnosed solid tumors. Traditional cancer treatments such as surgery, chemotherapy, and radiation therapy have been the mainstay for decades, but they are often accompanied by severe side effects and limited efficacy, especially in advanced-stage disease.

Immunotherapy has emerged as a transformative approach, engaging the host immune system in the detection and eradication of malignant cells. Its success in hematologic malignancies initially sparked interest, but its growing role in the treatment of solid tumors such as non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, and bladder cancer has cemented its status as a cornerstone of modern oncology.

Mechanism and Types of Immunotherapy

Immunotherapy works by modulating the immune system to enhance its natural ability to fight

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 06, June 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

cancer. One of the most successful forms is immune checkpoint inhibition. Cancer cells often evade immune detection by exploiting regulatory pathways like PD-1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). By blocking these checkpoints with monoclonal antibodies, such as pembrolizumab (anti-PD-1) or ipilimumab (anti-CTLA-4), T cells can remain activated and effectively target tumor cells.

Another major innovation is chimeric antigen receptor T-cell (CAR-T) therapy. Although CAR-T has shown more consistent efficacy in blood cancers, trials are underway to improve its performance in solid tumors through enhanced trafficking, persistence, and tumor microenvironment navigation.

Therapeutic cancer vaccines and oncolytic virus therapies are also under development. Personalized neoantigen vaccines are designed based on a patient's unique tumor mutational profile, aiming to stimulate a targeted immune response. Similarly, oncolytic viruses selectively infect and kill cancer cells while also activating systemic antitumor immunity.

Clinical Efficacy and Impact Across Solid Tumors

The impact of immunotherapy varies among different types of solid tumors but has significantly improved overall survival rates in many cases.

In non-small cell lung cancer (NSCLC), immune checkpoint inhibitors have changed the standard of care. A 2022 global study reported that PD-1 inhibitors improved 5-year survival rates from 16% to 31% in advanced NSCLC. In melanoma, which was once nearly uniformly fatal at stage IV, immunotherapy has extended median overall survival to more than 60 months in some patient groups, with a 5-year survival rate of approximately 52%.

Renal cell carcinoma (RCC) and urothelial carcinoma have also shown remarkable responses. Combination therapy involving nivolumab and ipilimumab in advanced RCC has demonstrated a 42% overall response rate, with durable outcomes in treatment-naïve patients.

Even in traditionally immunotherapy-resistant tumors, such as pancreatic and prostate cancer, there is growing evidence that combination regimens involving immunotherapy and chemotherapy or radiation may enhance responses.

Globally, it is estimated that over 35% of oncology treatment regimens now involve immunotherapy components, and by 2030, immunotherapies are projected to account for over 45% of the global oncology drug market, which is expected to surpass $375 billion USD.

Challenges and Limitations

Despite its promise, immunotherapy is not without challenges. Only a subset of

patients respond favorably, and reliable biomarkers for predicting response are still under investigation. PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) are currently used to select patients, but their predictive power is imperfect.

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 06, June 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

Furthermore, immune-related adverse events (irAEs) such as pneumonitis, colitis, endocrinopathies, and dermatitis can be severe and occasionally life-threatening. These side effects arise from the activation of T cells against normal tissues and require vigilant monitoring and management.

Another major hurdle is the immunosuppressive tumor microenvironment (TME) in many solid tumors, which includes regulatory T cells, myeloid-derived suppressor cells (MDSCs), and inhibitory cytokines. Strategies to remodel the TME, such as using oncolytic viruses or combining immunotherapy with anti-angiogenic agents, are under active investigation.

Future Directions and Innovations

The future of immunotherapy lies in personalization and combination therapy. Advances in artificial intelligence (AI) and genomics are accelerating the identification of tumor-specific neoantigens and patient-specific immune profiles. This will allow for precision immunotherapy, matching the right treatment to the right patient.

Combination approaches — involving immunotherapy with chemotherapy, radiation, targeted therapy, and even other immunotherapeutics — are expected to overcome resistance and enhance efficacy. Trials like CheckMate 9LA and KEYNOTE-189 have already demonstrated the benefits of such combinations in NSCLC and other cancers.

Another promising avenue is the use of bispecific T-cell engagers (BiTEs) and next-generation CAR-T therapies engineered to overcome the unique barriers posed by solid tumors.Moreover, the development of off-the-shelf (allogeneic) CAR-T cells, based on CRISPR-edited immune cells, could reduce cost and improve accessibility in the near future.

Conclusion

Immunotherapy has redefined the landscape of cancer treatment, particularly in the realm of solid tumors. Its capacity to produce durable responses and even potential cures in previously untreatable cancers signifies a new era in oncology. While challenges remain — including limited patient response rates, immune-related toxicity, and financial barriers — continued research and innovation offer a path toward overcoming these obstacles.

With ongoing investment in basic science, translational research, and global access strategies, immunotherapy is poised to become not just a treatment of last resort, but a frontline weapon in the fight against solid tumors.

References Uzbek Medical Sources:

1. G‘iyosov A.T., To‘xtasinova M.B. (2023). Zamonaviy onkologiyada immunoterapiya yondashuvlari. Toshkent: O‘zMU nashriyoti.

2. Raxmatova Z.B. (2022). Qattiq o‘simtalarni davolashda immunologik terapiyaning o‘rni. Samarqand: SamDTU ilmiy jurnali.

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 06, June 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

International Sources

3. World Health Organization (2023). Cancer Fact Sheet. Geneva: WHO.

4. Ribas A., Wolchok J.D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350–1355.

5. Hellmann M.D., et al. (2020). Nivolumab plus ipilimumab in advanced NSCLC. New England Journal of Medicine, 382(22), 2093–2104.

6. Hodi F.S., et al. (2018). Survival trends in advanced melanoma with checkpoint inhibitors. Journal of Clinical Oncology, 36(15), 1675–1684.

7. Sharma P., Allison J.P. (2020). The future of immune checkpoint therapy. Science, 348(6230), 56–61.

8. Hanna N.H., et al. (2021). Immunotherapy in solid tumors: From development to clinical implementation. The Lancet Oncology, 22(10), e450–e465.